Welcome to our dedicated page for Lilly Eli & Co news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly Eli & Co stock.
Eli Lilly and Company (NYSE: LLY) generates frequent news across cardiometabolic health, oncology, immunology, obesity and manufacturing expansion. This page aggregates recent press releases and third-party coverage so readers can follow how Lilly’s medicines, clinical programs and corporate actions are evolving over time.
Recent updates show Lilly reporting Phase 3 results for multiple late-stage assets. In obesity and cardiometabolic health, the company has shared topline data from ATTAIN-MAINTAIN, a Phase 3 trial of orforglipron, an investigational once-daily oral GLP-1 receptor agonist, for weight maintenance after prior treatment with injectable incretin therapies. Lilly has also reported results from TRIUMPH-4, a Phase 3 trial of retatrutide, an investigational triple agonist targeting GIP, GLP-1 and glucagon receptors, in adults with obesity or overweight and knee osteoarthritis, with co-primary endpoints in weight loss and pain reduction.
In immunology, Lilly has announced positive topline results from the TOGETHER-PsA Phase 3b trial, which evaluated concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) versus Taltz alone in adults with active psoriatic arthritis and obesity or overweight with at least one weight-related condition. The company reports that the combination met the primary endpoint and all key secondary endpoints, supporting an integrated approach to treating psoriatic arthritis and obesity.
Oncology news includes updated EMBER-3 data for Inluriyo (imlunestrant) as monotherapy and in combination with Verzenio (abemaciclib) in ER-positive, HER2-negative advanced breast cancer, and Phase 3 BRUIN CLL-313 results showing that Jaypirca (pirtobrutinib) significantly reduced the risk of progression or death versus chemoimmunotherapy in treatment-naïve CLL/SLL without 17p deletions.
Corporate and strategic news items cover Lilly’s planned acquisition of Ventyx Biosciences, completion of the Adverum Biotechnologies tender offer, a strategic collaboration with Aktis Oncology, and a major manufacturing investment in a new active pharmaceutical ingredient facility in Huntsville, Alabama. Investors and observers can use this news feed to monitor clinical milestones, regulatory submissions, acquisitions, collaborations, financing activities and manufacturing expansions related to LLY.
Eli Lilly and Company (NYSE: LLY) announced that Verzenio® (abemaciclib) combined with standard adjuvant endocrine therapy has met its primary endpoint of invasive disease-free survival, significantly reducing breast cancer recurrence risk in high-risk hormone receptor-positive (HR+), HER2- early breast cancer. This success, revealed in a Phase 3 monarchE study interim analysis, makes Verzenio the only CDK4 & 6 inhibitor to achieve such results. Lilly plans to present these findings at a medical meeting later this year and aims to submit data to regulatory authorities by the end of 2020.
The U.S. FDA has approved Lyumjev™ (insulin lispro-aabc injection) from Eli Lilly (NYSE: LLY), a rapid-acting insulin for adults with type 1 and type 2 diabetes. Lyumjev enhances glycemic control by mimicking natural insulin absorption, effectively reducing post-meal blood sugar spikes. The approval is based on Phase 3 studies, PRONTO-T1D and PRONTO-T2D, showing that Lyumjev outperforms Humalog in lowering A1C levels at 26 weeks. Lyumjev will be priced similarly to Humalog and is part of the Lilly Insulin Value Program, allowing affordable access to patients.
Eli Lilly and Company (NYSE: LLY) initiated a Phase 3 trial to assess the efficacy and safety of baricitinib in hospitalized adults with COVID-19. This randomized, double-blind, placebo-controlled study aims to enroll 400 patients across the U.S., Europe, and Latin America. Key endpoints include mortality rates and the requirement for mechanical ventilation by Day 28. Baricitinib is currently approved for rheumatoid arthritis and may mitigate COVID-19 complications by reducing hyperinflammation. Results are anticipated in the coming months as Lilly combats the pandemic and supports ongoing related research.
On June 13, 2020, Eli Lilly (NYSE: LLY) announced that Trulicity® (dulaglutide) exhibited significantly higher adherence and persistence compared to semaglutide and exenatide in type 2 diabetes patients. Presented at the ADA's 80th Scientific Sessions, the study utilized U.S. claims data, showing that after six months, 59.7% of Trulicity users adhered to treatment, compared to 42.7% for semaglutide and 58.1% versus 40.3% for exenatide. Moreover, treatment discontinuation rates were lower for Trulicity at 30.8%, compared to 40.8% and 32.1% for its competitors.